These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 23998921)
21. Recent advances in understanding the mechanism of action of bisphosphonates. Coxon FP; Thompson K; Rogers MJ Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801 [TBL] [Abstract][Full Text] [Related]
22. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623 [TBL] [Abstract][Full Text] [Related]
23. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Rondeau JM; Bitsch F; Bourgier E; Geiser M; Hemmig R; Kroemer M; Lehmann S; Ramage P; Rieffel S; Strauss A; Green JR; Jahnke W ChemMedChem; 2006 Feb; 1(2):267-73. PubMed ID: 16892359 [TBL] [Abstract][Full Text] [Related]
24. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Tsoumpra MK; Muniz JR; Barnett BL; Kwaasi AA; Pilka ES; Kavanagh KL; Evdokimov A; Walter RL; Von Delft F; Ebetino FH; Oppermann U; Russell RGG; Dunford JE Bone; 2015 Dec; 81():478-486. PubMed ID: 26318908 [TBL] [Abstract][Full Text] [Related]
25. New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs. Fernández D; Ramis R; Ortega-Castro J; Casasnovas R; Vilanova B; Frau J J Comput Aided Mol Des; 2017 Jul; 31(7):675-688. PubMed ID: 28631130 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326 [TBL] [Abstract][Full Text] [Related]
27. Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase. Rodriguez JB; Falcone BN; Szajnman SH Expert Opin Drug Discov; 2016; 11(3):307-20. PubMed ID: 26781029 [TBL] [Abstract][Full Text] [Related]
28. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors. Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954 [TBL] [Abstract][Full Text] [Related]
29. Nitrogen-containing bisphosphonate mechanism of action. Reszka AA; Rodan GA Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639 [TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates. Liu QZ; Wang SS; Li X; Zhao XY; Li K; Lv GC; Qiu L; Lin JG Chem Biol Drug Des; 2018 Mar; 91(3):735-746. PubMed ID: 29080272 [TBL] [Abstract][Full Text] [Related]
31. Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa. Schmidberger JW; Schnell R; Schneider G Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):721-31. PubMed ID: 25760619 [TBL] [Abstract][Full Text] [Related]
32. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Aripirala S; Gonzalez-Pacanowska D; Oldfield E; Kaiser M; Amzel LM; Gabelli SB Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):802-10. PubMed ID: 24598749 [TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates: mode of action and pharmacology. Russell RG Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236 [TBL] [Abstract][Full Text] [Related]
34. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Jahnke W; Rondeau JM; Cotesta S; Marzinzik A; Pellé X; Geiser M; Strauss A; Götte M; Bitsch F; Hemmig R; Henry C; Lehmann S; Glickman JF; Roddy TP; Stout SJ; Green JR Nat Chem Biol; 2010 Sep; 6(9):660-6. PubMed ID: 20711197 [TBL] [Abstract][Full Text] [Related]
35. Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. Lacbay CM; Waller DD; Park J; Gómez Palou M; Vincent F; Huang XF; Ta V; Berghuis AM; Sebag M; Tsantrizos YS J Med Chem; 2018 Aug; 61(15):6904-6917. PubMed ID: 30016091 [TBL] [Abstract][Full Text] [Related]
36. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819 [TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Drake MT; Cremers SC Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033 [TBL] [Abstract][Full Text] [Related]